ProfileGDS5678 / 1417951_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 95% 97% 70% 86% 70% 72% 72% 80% 71% 70% 70% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4905971
GSM967853U87-EV human glioblastoma xenograft - Control 28.3820995
GSM967854U87-EV human glioblastoma xenograft - Control 39.6247497
GSM967855U87-EV human glioblastoma xenograft - Control 44.4225470
GSM967856U87-EV human glioblastoma xenograft - Control 56.5114686
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3801470
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5748172
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.557872
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6753780
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4342971
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.3320270
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3228770
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4777271
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4742871